Suppression of angiogenesis and tumor growth by adenoviral-mediated gene transfer of pigment epithelium-derived factor

Molecular Therapy

Volumn 8, Issue 1, 2003, Pages 72-79

  Wang, Lin ^a,b   Schmitz, Volker ^a,c   Perez Mediavilla, Alberto ^a   Izal, Iñigo ^a   Prieto, Jesus ^a   Qian, Cheng ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b JILIN UNIVERSITY   (China)

^c UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Adenovirus; Angiogenesis; Animal models; Gene therapy; Pigment epithelium derived factor; Tumor

Indexed keywords

ADENOVIRUS VECTOR; ANGIOGENESIS INHIBITOR; MATRIGEL; PIGMENT EPITHELIUM DERIVED FACTOR; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CULTURE; CELL MIGRATION; CONTROLLED STUDY; CYTOMEGALOVIRUS; ENDOTHELIUM CELL; FEMALE; GENE OVEREXPRESSION; GENE TRANSFER; GENETIC CODE; IN VIVO STUDY; LIVER CELL CARCINOMA; LUNG CARCINOMA; MOUSE; NEUROTROPISM; NONHUMAN; TUMOR VASCULARIZATION; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALIA; CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS; MUS MUSCULUS;

EID: 0043201411     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-0016(03)00128-X     Document Type: Article

References (45)

1. Tombran-Tink, J., Chader, G. G., and Johnson, L. V. (1991). PEDF: a pigment epithelium-derived factor with potent neuronal differentiative activity. Exp. Eye Res. 53: 411-414.
2. Becerra, S., Sagasti, A., Spinella, P., and Notario, V. (1995). Pigment epithelium-derived factor behaves like a noninhibitory serpin: neurotrophic activity does not require the serpin reactive loop. J. Biol. Chem. 270: 25992-25999.
3. DeCoster, M. A., Schabelman, E., Tombran-Tink, J., and Bazan, N. G. (1999). Neuroprotection by pigment epithelial-derived factor against glutamate toxicity in developing primary hippocampal neurons. J. Neurosci. Res. 56: 604-610.
4. Araki, T., Taniwaki, T., Becerra, S. P., Chader, G. J., and Schwartz, J. P. (1998). Pigment epithelium-derived factor (PEDF) differentially protects immature but not mature cerebellar granule cells against apoptotic cell death. J. Neurosci. Res. 53: 7-15.
5. Bilak, M. M., Corse, A. M., Bilak, S. R., Lehar, M., Tombran-Tink, J., and Kuncl, R. W. (1999). Pigment epithelium-derived factor (PEDF) protects motor neurons from chronic glutamate-mediated neurodegeneration. J. Neuropathol. Exp. Neurol. 58: 719-728.
6. Yabe, T., Wilson, D., and Schwartz, J. P. (2001). NFkappaB activation is required for the neuroprotective effects of pigment epithelium-derived factor (PEDF) on cerebellar granule neurons. J. Biol. Chem. 276: 43313-43319.
7. Cayouette, M., Smith, S. B., Becerra, S. P., and Gravel, C. (1999). Pigment epithelium-derived factor delays the death of photoreceptors in mouse models of inherited retinal degenerations. Neurobiol. Dis. 6: 523-532.
8. Dawson, D. W., et al. (1999). Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285: 245-248.
9. Gao, G., Li, Y., Zhang, D., Gee, S., Crosson, C., and Ma, J. (2001). Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization. FEBS Lett. 489: 270-276.
10. Spranger, J., et al. (2001). Loss of the antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye disease. Diabetes 50: 2641-2645.
11. King, G. L., and Suzuma, K. (2000). Pigment-epithelium-derived factor - A key coordinator of retinal neuronal and vascular functions. N. Engl. J. Med. 342: 349-351.
12. Chader, G. J. (2001). PEDF: raising both hopes and questions in controlling angiogenesis. Proc. Natl. Acad. Sci. USA 98: 2122-2124.
13. Stellmach, V., Crawford, S. E., Zhou, W., and Bouck, N. (2001). Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor. Proc. Natl. Acad. Sci. USA 98: 2593-2597.
14. Mori, K., et al. (2001). Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. J. Cell. Physiol. 188: 253-263.
15. Folkman, J. (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1: 27-31.
16. Carmeliet, P., and Jain, R. K. (2000). Angiogenesis in cancer and other diseases. Nature 407: 249-257.
17. Folkman, J. (1990). What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 82: 4-6.
18. Hanahan, D., and Folkman, J. (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364.
19. Conway, E. M., Collen, D., and Carmeliet, P. (2001). Molecular mechanisms of blood vessel growth. Cardiovasc. Res. 49: 507-521.
20. Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., and Holash, J. (2000). Vascular-specific growth factors and blood vessel formation. Nature 407: 242-248.
21. Claffey, K. P., et al. (1996). Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res. 56: 172-181.
22. Kandel, J., Bossy-Wetzel, E., Radvanyi, F., Klagsbrun, M., Folkman, J., and Hanahan, D. (1991). Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 66: 1095-1104.
23. Dameron, K. M., Volpert, O. V., Tainsky, M. A., and Bouck, N. (1994). Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265: 1582-1584.
24. O'Reilly, M. S., et al. (1994). Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315-328.
25. O'Reilly, M. S., et al. (1997). Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285.
26. Jimenez, B., Volpert, O. V., Crawford, S. E., Febbraio, M., Silverstein, R. L., and Bouck, N. (2000). Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat. Med. 6: 41-48.
27. Gao, G., et al. (2002). Down-regulation of VEGF and up-regulation of PEDF: a possible mechanism for the anti-angiogenic activity of plasminogen kringle 5. J. Biol. Chem. 277: 9492-9497.
28. Asahara, T., et al. (1999). Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ. Res. 85: 221-228.
29. Lyden, D., et al. (2001). Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 7: 1194-1201.
30. Moore, M. A. S. (2002). Putting the neo into neoangiogenesis. J. Clin. Invest. 109: 313-315.
31. Reyes, M., Dudek, A., Jahagirdar, B., Koodie, L., Marker, P. H., and Verfaillie, C. M. (2002). Origin of endothelial progenitors in human postnatal bone marrow. J. Clin. Invest. 109: 337-346.
32. Lin, Y., Weisdorf, D. J., Solovey, A., and Hebbel, R. P. (2000). Origins of circulating endothelial cells and endothelial outgrowth from blood. J. Clin. Invest. 105: 71-77.
33. Rafii, S. (2000). Circulating endothelial precursors: mystery, reality, and promise. J. Clin. Invest. 105: 17-19.
34. Ito, H., et al. (1999). Endothelial progenitor cells as putative targets for angiostatin. Cancer Res. 59: 5875-5877.
35. Kleinman, H. K., and Liau, G. (2001). Gene therapy for antiangiogenesis. J. Natl. Cancer Inst. 93: 965-967.
36. Kong, H. L., and Crystal, R. G. (1998). Gene therapy strategies for tumor antiangiogenesis. J. Natl. Cancer Inst. 90: 273-286.
37. Folkman, J. (1998). Antiangiogenic gene therapy. Proc. Natl. Acad. Sci. USA 95: 9064-9066.
38. Morral, N., et al. (1999). Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc. Natl. Acad. Sci. USA 96: 12816-12821.
39. Kochanek, S. (1999). High-capacity adenoviral vectors for gene transfer and somatic gene therapy. Hum. Gene Ther. 10: 2451-2459.
40. Pfeifer, A., Kessler, T., Silletti, S., Cheresh, D. A., and Verma, I. M. (2000). Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2. Proc. Natl. Acad. Sci. USA 97: 12227-12232.
41. Qian, C., Bilbao, R., Bruna, O., and Prieto, J. (1995). Induction of sensitivity to ganciclovir in human hepatocellular carcinoma cells by adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase. Hepatology 22: 118-123.
42. Volin, M. V., et al. (1999). Treatment with sulfasalazine or sulfapyridine, but not 5-aminosalicylic acid, inhibits basic fibroblast growth factor-induced endothelial cell chemotaxis. Arthritis Rheum. 42: 1927-1935.
43. Yao, L., et al. (1999). Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood 93: 1612-1621.
44. Coughlin, C. M., et al. (1998). Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J. Clin. Invest 101: 1441-1452.
45. Weidner, N., Semple, J. P., Welch, W. R., and Folkman, J. (1991). Tumor angiogenesis and metastasis - Correlation in invasive breast carcinoma. N. Engl. J. Med. 324: 1-8.